Implementation of lower doses of PD-1 inhibitors might be efficacious in IPF patients with specific immune profile, while concomitantly spare adverse events of PD-1 inhibitors such as pneumonitis [40–42]. This evidence concerns the gene PDCD1 and pneumonitis.